FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2007242643> ?p ?o ?g. }

• W2007242643 endingPage "767" @default.
• W2007242643 startingPage "761" @default.
• W2007242643 abstract "Optimal platelet inhibition is an important therapeutic adjunct in patients with carotid artery stenosis undergoing carotid artery stenting (CAS). Clopidogrel resistance is associated with increased periprocedural thromboembolic complications from neurovascular stent placement procedures. The addition of cilostazol to dual antiplatelet therapy (DAT) has been reported to reduce platelet reactivity and to improve clinical outcomes after percutaneous coronary intervention. This study was undertaken to evaluate the impact of adjunctive cilostazol in patients with CAS.Platelet function was assessed by light transmittance aggregometry using the VerifyNow assay. Sixty-four consecutive patients who underwent CAS received standard DAT, clopidogrel (75 mg daily), and aspirin (100 mg daily) more than 4 weeks before the procedure. From 2010 to 2011 (period I), 28 patients underwent CAS under standard DAT. From 2011 to 2013 (period II), 36 patients prospectively had preoperative assessment of platelet function, and 13 patients with clopidogrel resistance received adjunctive cilostazol (200 mg daily) in addition to standard DAT. The incidence of new ipsilateral ischemic lesions on diffusion-weighted imaging a day after CAS and ischemic or hemorrhagic events within 30 days was assessed.Clopidogrel resistance was indentified in 12 patients (43%) in period I and 13 patients (36%) in period II (P = .615). In period II, the addition of cilostazol significantly decreased P2Y12 reaction units and % inhibition (P = .006 and P = .005, respectively), and there was a significant difference in P2Y12 reaction units between the two periods. New ipsilateral ischemic lesions were significantly decreased in period II (2/36 patients) compared with period I (7/28 patients; P = .034); however, there was no significant difference in hemorrhagic and thromboembolic events between the two periods.Adjunctive cilostazol (triple antiplatelet therapy) in clopidogrel-resistant patients reduces the rate of clopidogrel resistance and suppresses new ischemic lesions without hemorrhagic complications, as compared with standard DAT. Antiplatelet management based on the evaluation of antiplatelet resistance would be required for prevention of perioperative thromboembolic complications in CAS." @default.
• W2007242643 created "2016-06-24" @default.
• W2007242643 creator A5002830709 @default.
• W2007242643 creator A5018526643 @default.
• W2007242643 creator A5029714930 @default.
• W2007242643 creator A5036383115 @default.
• W2007242643 creator A5060268134 @default.
• W2007242643 creator A5078888657 @default.
• W2007242643 creator A5080351529 @default.
• W2007242643 creator A5084912887 @default.
• W2007242643 date "2014-03-01" @default.
• W2007242643 modified "2023-10-14" @default.
• W2007242643 title "Platelet inhibition by adjunctive cilostazol suppresses the frequency of cerebral ischemic lesions after carotid artery stenting in patients with carotid artery stenosis" @default.
• W2007242643 cites W18470154 @default.
• W2007242643 cites W1974655135 @default.
• W2007242643 cites W1978242119 @default.
• W2007242643 cites W1979128772 @default.
• W2007242643 cites W1996403145 @default.
• W2007242643 cites W2001759058 @default.
• W2007242643 cites W2014459583 @default.
• W2007242643 cites W2015521606 @default.
• W2007242643 cites W2024806075 @default.
• W2007242643 cites W2030244779 @default.
• W2007242643 cites W2035061332 @default.
• W2007242643 cites W2038169486 @default.
• W2007242643 cites W2049913259 @default.
• W2007242643 cites W2058971526 @default.
• W2007242643 cites W2068804349 @default.
• W2007242643 cites W2071252381 @default.
• W2007242643 cites W2081100231 @default.
• W2007242643 cites W2099884864 @default.
• W2007242643 cites W2100194095 @default.
• W2007242643 cites W2105489963 @default.
• W2007242643 cites W2111691562 @default.
• W2007242643 cites W2130468498 @default.
• W2007242643 cites W2145425156 @default.
• W2007242643 cites W2148944238 @default.
• W2007242643 cites W2149287342 @default.
• W2007242643 cites W2149852683 @default.
• W2007242643 cites W2162214454 @default.
• W2007242643 cites W2163119611 @default.
• W2007242643 cites W2317492427 @default.
• W2007242643 doi "https://doi.org/10.1016/j.jvs.2013.09.011" @default.
• W2007242643 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24239116" @default.
• W2007242643 hasPublicationYear "2014" @default.
• W2007242643 type Work @default.
• W2007242643 sameAs 2007242643 @default.
• W2007242643 citedByCount "26" @default.
• W2007242643 countsByYear W20072426432014 @default.
• W2007242643 countsByYear W20072426432015 @default.
• W2007242643 countsByYear W20072426432016 @default.
• W2007242643 countsByYear W20072426432017 @default.
• W2007242643 countsByYear W20072426432018 @default.
• W2007242643 countsByYear W20072426432019 @default.
• W2007242643 countsByYear W20072426432020 @default.
• W2007242643 countsByYear W20072426432021 @default.
• W2007242643 countsByYear W20072426432022 @default.
• W2007242643 countsByYear W20072426432023 @default.
• W2007242643 crossrefType "journal-article" @default.
• W2007242643 hasAuthorship W2007242643A5002830709 @default.
• W2007242643 hasAuthorship W2007242643A5018526643 @default.
• W2007242643 hasAuthorship W2007242643A5029714930 @default.
• W2007242643 hasAuthorship W2007242643A5036383115 @default.
• W2007242643 hasAuthorship W2007242643A5060268134 @default.
• W2007242643 hasAuthorship W2007242643A5078888657 @default.
• W2007242643 hasAuthorship W2007242643A5080351529 @default.
• W2007242643 hasAuthorship W2007242643A5084912887 @default.
• W2007242643 hasBestOaLocation W20072426431 @default.
• W2007242643 hasConcept C126322002 @default.
• W2007242643 hasConcept C164705383 @default.
• W2007242643 hasConcept C2777628954 @default.
• W2007242643 hasConcept C2777849778 @default.
• W2007242643 hasConcept C2779169563 @default.
• W2007242643 hasConcept C2779820409 @default.
• W2007242643 hasConcept C2780007028 @default.
• W2007242643 hasConcept C2780400711 @default.
• W2007242643 hasConcept C2781068581 @default.
• W2007242643 hasConcept C3018162438 @default.
• W2007242643 hasConcept C42219234 @default.
• W2007242643 hasConcept C500558357 @default.
• W2007242643 hasConcept C71924100 @default.
• W2007242643 hasConceptScore W2007242643C126322002 @default.
• W2007242643 hasConceptScore W2007242643C164705383 @default.
• W2007242643 hasConceptScore W2007242643C2777628954 @default.
• W2007242643 hasConceptScore W2007242643C2777849778 @default.
• W2007242643 hasConceptScore W2007242643C2779169563 @default.
• W2007242643 hasConceptScore W2007242643C2779820409 @default.
• W2007242643 hasConceptScore W2007242643C2780007028 @default.
• W2007242643 hasConceptScore W2007242643C2780400711 @default.
• W2007242643 hasConceptScore W2007242643C2781068581 @default.
• W2007242643 hasConceptScore W2007242643C3018162438 @default.
• W2007242643 hasConceptScore W2007242643C42219234 @default.
• W2007242643 hasConceptScore W2007242643C500558357 @default.
• W2007242643 hasConceptScore W2007242643C71924100 @default.
• W2007242643 hasIssue "3" @default.
• W2007242643 hasLocation W20072426431 @default.
• W2007242643 hasLocation W20072426432 @default.
• W2007242643 hasOpenAccess W2007242643 @default.

• next